By using estrogen receptor α (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2) status as a surrogate for gene expression profiling, breast cancers are commonly classified into luminal, HER2+, and triple-negative subtypes [1, 2]. This evidence concerns the gene ESR1 and breast cancer.